Chemotherapy-induced nausea and vomiting with special emphasis on metopimazine

Danish Medical Bulletin

Volumn 45, Issue 4, 1998, Pages 412-422

  Herrstedt, Jørn ^a,b,c  

^a BISPEBJERG HOSPITAL   (Denmark)

^b Mental Health Services CPH   (Denmark)

^c Department of Oncology ^*

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; BENZODIAZEPINE DERIVATIVE; BLEOMYCIN; CARBOPLATIN; CHLORMETHINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DACTINOMYCIN; DAUNORUBICIN; DOPAMINE RECEPTOR BLOCKING AGENT; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; HYDROXYUREA; LOMUSTINE; METHOTREXATE; METOCLOPRAMIDE; METOPIMAZINE; MITOMYCIN C; PROCARBAZINE; SEROTONIN ANTAGONIST; STEROID; TAXANE DERIVATIVE; TENIPOSIDE; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

CANCER CHEMOTHERAPY; DRUG EFFICACY; DRUG MECHANISM; HUMAN; HUMAN CELL; HUMAN TISSUE; NAUSEA; PATHOPHYSIOLOGY; PROGNOSIS; REVIEW; VOMITING;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; HUMANS; ISONIPECOTIC ACIDS; NAUSEA; VOMITING;

EID: 0031703793     PISSN: 09078916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (168)

1. Aapro MS. Controlling emesis related to cancer chemotherapy. Eur J Cancer 1991; 27(3): 356-361.
2. 3 receptor antagonists. An overview of their present status and future potential in cancer therapy-induced emesis. Drugs 1991; 42(4): 551-568.
3. Alfieri AB & Cubeddu LX. Treatment with para-chlorophenylalanine antagonises the emetic response and the serotonin-releasing actions of cisplatin in cancer patients. Br J Cancer 1995; 71: 629-632.
4. Allen JC, Gralla RJ, Reilly C et al. Metoclopramide: dose-refated toxicity and preliminary antiemetic studies in children receiving cancer chemotherapy. J Clin Oncol 1985; 3: 1136-1141.
5. Andrews PLR, Davis CJ, Bingham S et al. The abdominal visceral innervation and the emetic reflex: pathways, pharmacology, and plasticity. Can J Physiol Pharmacol 1990; 68: 325-345.
6. Angelo HR, Herrstedt J, Jørgensen M. A high-performance liquid Chromatographic method with fluorescence detection for the simultaneous determination of metopimazine and its acid metabolite in serum. J Chromatography 1989; 496: 472-477.
7. Baker JJ, Lokey JL, Price NA et al. Nabilone as an antiemetic (letter). N Engl J Med 1979; 321: 728.
8. Beck TM, Hesketh PJ, Madajewicz S et al. Stratified randomized, double-blind comparison of intravenous ondansetron administered as a multipledose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting. J Clin Oncol 1992; 10: 1969-1975.
9. Bonneterre J, Chevallier B, Metz R et al. A randomized, double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil and doxorubicin or epirubicin chemotherapy. J Clin Oncol 1990; 8(6): 1063-1069.
10. Borison HL & Wang SC. Physiology and pharmacology of vomiting. Pharmacol Rev 1953; 5: 193-230.
11. Borison HL & McCarthy LE. Neuropharmacology of chemotherapy-induced emesis. Drugs 1983; 25(suppl 1): 8-17.
12. Bradley PB, Engel G, Feniuk W et al. Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. Neuropharmacol 1986; 25(6): 563-576.
13. Bregni M, Siena S, Di Nicola M, Bonadonna G, Gianni AM. Tropisetron plus haloperidol to ameliorate nausea and vomiting associated with high-dose alkylating agent chemotherapy. Eur J Cancer 1991; 27: 561-565.
14. Campbell M, Bateman DN. Pharmacokinetic optimisation of antiemetic therapy. Clin Pharmacokin 1992; 23(2): 147-160.
15. Carl PL, Cubeddu LX, Lindley C, Myers RD, Rezvani AH. Do humoral factors mediate cancer chemotherapy-induced emesis? Drug Metab Rev 1989; 21: 319-333.
16. Carmichael J, Bessel EM, Harris AL, Hutcheon AW, Dawes PJDK, Daniels S. Comparison of granisetron alone and granisetron plus dexamethasone in the prophylaxis of cytotoxic-induced emesis. Br J Cancer 1994; 70: 1161-1164.
17. Carpenter DO. Neural mechanisms of emesis. Can J Physiol Pharmacol 1990; 68: 230-236.
18. Carr BI, Blayney DW, Goldberg DA, Braly P, Mener GE, Doroshow JH. High doses of prochiorperazine for cisplatin-induced emesis. A prospective, random, dose-response study. Cancer 1987; 60: 2165-2169.
19. Chevallier B, Marry M, Paillarse J-M et al. Methylprednisolone enhances the efficacy of ondansetron in acute and delayed cisplatin-induced emesis over at least three cycles. Br J Cancer 1994; 70: 1171-1175.
20. Clavel M, Bolot JE, Philippe-Bert J, Putot JP, Rodary C, Pommatau E. Essai comparatif en double insu de deux doses i.v. (50 mg et 10 mg) de metopiniazine (1) dans le prévention de nausées et des vomissements de la chimiothérapie anticancéreuse. Lyon Med 1978; 239: 307-309.
21. Coates A, Abraham S, Kaye SB et al. On the receiving end-patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 1983; 19: 203-208.
22. Cognetti F, Pinnaro P, Carlini P et al. Randomized open cross-over trial between metoclopramide and dexamethasone for the prevention of cisplatininduced nausea and vomiting. Eur J Cancer Clin Oncol 1984; 20: 183-187.
23. Costall B, Domeney AM, Naylor RJ et al. 5-hydroxytryptamine M-receptor antagonism to prevent cisplatin-induced emesis. Neuropharmacology 1986; 25: 959-961.
24. Craig JB, Powell BL, White DR, Capizzi RL. Antiemetic therapy in patients treated with high-dose cytosine arabinoside. Oncology 1987; 44: 90-92.
25. Cubeddu LX, Hoffmann IS, Fuenmayor NT, Finn AL. Antagonism of serotonin S3 receptors with ondansetron prevents nausea and vomiting induced by cyclophosphamide-containing regimens, J Clin Oncol 1990a; 8: 1721-1727.
26. Cubeddu LX, Hoffmann IS, Fuenmayor NT, Finn AL. Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. N Engl J Med 1990b; 322: 810-816.
27. Cubeddu LX, Hoffmann IS, Fuenmayor NT, Malave JJ. Changes in serotonin metabolism in cancer patients: its relationship to nausea and vomiting induced by chemotherapeutic drugs. Br J Cancer 1992; 66: 198-203.
28. Cubeddu LX & Hoffmann IS. Participation of serotonin on early and delayed emesis induced by initial and subsequent cycles of cisplatinum-based chemotherapy: effects of antiemetics. J Clin Pharmacol 1993; 33: 691-697.
29. Cunningham D, Evans C, Gazet J-C et al. Comparison of antiemetic efficacy of domperidone, metoclopramide, and dexamethasone in patients receiving outpatient chemotherapy regimens. BMJ 1987; 295: 250.
30. Cupissol DR, Serrou B, Caubel M. The efficacy of granisetron as a prophylactic anti-emetic and intervention agent in high-dose cisplatin-induced emesis. Eur J Cancer 1990; 26(suppl 1): S23-S27.
31. D'Acquisto RW, Tyson LB, Gralla RJ et al. The influence of chronic high alcohol intake on chemotherapy-induced nausea and vomiting. Proc Am Soc Clin Oncol 1986; 5: 257.
32. Dana BW, Everts EC & Dickinson D. Dexamethasone vs. placebo for cisplatin-induced emesis. A randomized cross-over trial. Am J Clin Oncol (CCT) 1985; 8: 426-428.
33. David M, Durand M, Chauvergne J et al. Cyclophosphamide, methotrexate, and 5-FU (CMF)-induced nausea and vomiting: a controlled study with high-dose metoclopramide. Cancer Treat Rep 1984; 68: 921-922.
34. De Boer AG. "First pass" elimination of some high-clearance drugs following rectal administration to humans and rats. Ph.D thesis (University of Leiden, The Nederlands 1979).
35. Del Favero A, Roila F, Tonato M. Reducing chemotherapy-induced nausea and vomiting: current perspectives and future possibilities. Drug Safety 1993; 9(6): 410-428.
36. De Mulder HM, Seynaeve C, Vermerken JB et al. Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatininduced nausea and vomiting. Ann Intern Med 1990; 113: 834-840.
37. Dicato MA. Oral treatment with ondansetron in an outpatient setting. Eur J Cancer 1991; 27(suppl 1):S18-S19.
38. D'Olimpio JT, Camacho F, Chandra P et al. Antiemetic efficacy of high-dose dexamethasone versus placebo in patients receiving cisplatin-based chemotherapy: a randomized double-blind controlled clinical trial. J Clin Oncol 1985; 3: 1133-1135.
39. Du Bois A, Meerpohl HG, Vach W et al. Course, patterns and risk-factors for chemotherapy-induced emesis in cispiatin-pretreated patients: a study with ondansetron. Eur J Cancer 1992; 28: 450-457.
40. Petting JH, Grochow LB, Folstein MF et al. The course of nausea and vomiting after high-dose Cyclophosphamide. Cancer Treat Rep 1982; 66: 1487-1493.
41. Foster BJ, Newell DR, Gumbrell LA, Jenns ICE, Calvert AH. Phase I trial with pharmacokinetics of CB10-277 given by 24 hours continuous infusion. Br J Cancer 1993; 67: 369-373.
42. Fozard JR. Neuronal 5-HT receptors in the periphery. Neuropharmacology 1984; 23: 1473-1486.
43. Fredrikson M, Hursti TJ, Steineck G, Fürst CJ, Börjeson S, Peterson C. Delayed chemotherapy-induced nausea is augmented by high levels of endogenous noradrenaline. Br J Cancer 1994; 70: 642-645.
44. Fukui H, Yamamoto M, Sasaki S, Sato S. Possible involvement of peripheral 5-HT4 receptors in copper sulphate-induced vomiting in dogs. Eur J Pharmacol 1994; 257: 47-52.
45. Gaddum JH, Picarelli ZP. Two kinds of tryptamine receptor. Br J Pharmac Chemother 1957; 12: 323-328.
46. Gardner CJ, Twissell DJ, Dale TJ et al. The broad-spectrum anti-emetic activity of the novel non-peptide tachykinin NK receptor antagonist GR203040. Br J Pharmacol 1995; 116(8): 3158-3163.
47. Gordon CJ, Pazdur R, Zicarelli A, Cummings G, Al-Sarraf M. Metoclopramide versus metoclopramide and lorazepam: superiority of combined therapy in the control of cisplatin-induced emesis. Cancer 1989; 63: 578-582.
48. Gralla RJ, Braun TJ, Squillante Aet al. Metoclopramide: initial clinical studies of high dosage regimens in cisplatin-induced emesis. In Poster D (ed): The treatment of nausea and vomiting induced by cancer chemotherapy. New York, Masson Publishing, 1981a; 167-176.
49. Gralla RJ, Itri L, Pisko S et al. Antiemetic efficacy of high dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced vomiting. N Engl J Med 1981b; 305: 905-909.
50. Gralla RJ, Tyson LB, Kris MG & Clark RA. The management of chemotherapy-induced nausea and vomiting. Med Clin North Am 1987; 71(2): 289-301.
51. Griffin AM, Butow PN, Coates AS et al. On the receiving end V: Patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol 1996; 7:189-195.
52. Grunberg SM. Potential for combination therapy with the new antiserotonergic agents. Eur J Cancer 1993; 29A(suppl 1): S39-S41.
53. Grunberg SM, McDermed JE, Bernstein L & Cohen JL. Examination of the correlation of serum metoclopramide levels with antiemetic efficacy in patients receiving cisplatin. Cancer Chemother Pharmacol 1987; 20:332-336.
54. Grunberg SM, Hesketh PJ. Review article: control of chemotherapy-induced emesis. N Engl J Med 1993; 329: 1790-1796.
55. Grunberg SM, Gala KV, Lampenfeld M et al. Comparison of the antiemetic effect of high-dose intravenous metoclopramide and high-dose intravenous haloperidol in a randomized double-blind crossover study. J Clin Oncol 1984; 2(7): 782-787.
56. Hainsworth J, Harvey W, Pendergrass K et al. A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy. J Clin Oncol 1991; 9: 721-728.
57. Harrington RA, Hamilton CW, Brogden RN, Linkewich JA, Romankiewicz JA, Heel RC. Metoclopramide. An updated review of its pharmacological properties and clinical use. Drugs 1983; 25: 451-494.
58. Harris AL. Cytotoxic therapy-induced vomiting is mediated via enkephalin pathways. Lancet 1982; i: 714-716.
59. Hatcher RA & Weiss S. Studies on vomiting. J Pharm Exper Therap 1923; 22(3): 139-193.
60. Havsteen H & Kjær M. Medical treatment of nausea and vomiting caused by cancer chemotherapy. Ugeskr Laeger 1989; 151: 430-434.
61. Havsteen H, Kjær M. Double-blind randomized cross-over trial comparing methylprednisolone with placebo in chemotherapy-induced nausea and vomiting: a study with special reference to efficacy parameters. Anti-Cancer Drugs 1991; 2: 571-579.
62. Heron JF, Goedhals L, Jordaan JP et al. Oral granisetron alone and in combination with dexamethasone: a double-blind randomized comparison against high-dose metoclopramide plus dexamethasone in prevention of cisplatin-induced emesis. Ann Oncol 1994; 5: 579-584.
63. Herrstedt J, Dombernowsky P. Treatment of chemotherapy-induced nausea and vomiting. Ugeskr Laeger 1994a; 156: 453-460.
64. Herrstedt J. Development of antiemetic therapy in cancer patients. Acta Oncol 1995; 34(5): 637-640.
65. Herrstedt J, Hannibal J, Hallas J, Andersen E, Lauersen LC, Hansen M. High-dose metoclopramide + lorazepam versus low-dose metoclopramide + lorazepam + dehydrobenzperidol in the treatment of cisplatin-induced nausea and vomiting. Ann Oncol 1991a; 2: 223-227.
66. 1-adrenergic receptors. Cancer Chemother Pharmacol 1993a;33: 53-56.
67. Herrstedt J, Jørgensen M, Angelo HR. The effect of food on serum concentrations of metopimazine. Br J Clin Pharmacol 1990; 30: 237-243.
68. Herrstedt J, Jørgensen M, Angelo HR, Rassing MR, Møller-Sonnergaard J, Dombernowsky P. Bioavailability of the antiemetic metopimazine given as a microenema. Br J Clin Pharmacol 1996; 41:613-615.
69. Herrstedt J, Sigsgaard T, Angelo HR, Hansen M. Dose finding study of oral metopimazine. Support Care Cancer 1997a; 5: 38-43.
70. Herrstedt J, Sigsgaard T, Boesgaard M, Jensen TP, Dombernowsky P. Ondansetron plus metopimazine compared with ondansetron alone in patients receiving moderately emetogenic chemotherapy. N Engl J Med 1993b; 328: 1076-1080.
71. Herrstedt J, Sigsgaard T, Handberg J, Schousboe BMB, Hansen M, Dombernowsky P. Randomized, double-blind comparison of ondansetron versus ondansetron plus metopimazine as antiemetic prophylaxis during platinum-based chemotherapy in patients with cancer. J Clin Oncol 1997b; 15: 1690-1696.
72. Herrstedt J. We still need common criteria for the assessment of nausea and vomiting. Eur J Cancer 1994b; 30A(9): 1217.
73. 3-antagonist batanopride (BMY-25801). Ann Oncol 1991b; 2: 154-155
74. Hesketh PJ, Harvey WH, Harker WG et al. A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis. J Clin Oncol 1994; 12: 596-600.
75. Homesley HD, Gainey JM, Jobson VN et al. Double-blind placebo-controlled study of metoclopramide in cisplatin-induced emesis. N Engl J Med 1982; 307:250-251.
76. Hulstaert F, Van Belle S, Bleiberg H et al. Optimal combination therapy with tropisetron in 445 patients with incomplete control of chemotherapy-induced nausea and vomiting. J Clin Oncol 1994; 12: 2439-2446.
77. Ison PJ & Peroutka SJ. Neurotransmitter receptor binding studies predict antiemetic efficacy and side effects. Cancer Treat Rep 1986; 70: 637-641.
78. Israel L, Rodary C. Treatment of nausea and vomiting related to anticancerous multiple combination chemotherapy: results of two controlled studies. J Int Med Res 1978; 6: 235-240.
79. Italian Group for Antiemetic Research. Ondansetron + dexamethasone vs metoclopramide + dexamethasone + diphenhydramine in prevention of cisplatin-induced emesis. Lancet 1992; 340: 96-99.
80. Italian Group for Antiemetic Research. Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Ann Oncol 1995a; 6: 805-810.
81. Italian Group for Antiemetic Research. Dexamethasone, granisetron or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 1995b; 332: 1-5.
82. Italian Group for Antiemetic Research. Persistence of efficacy of three antiemetic regimens and prognostic factors in patients undergoing moderately emetogenic chemotherapy. J Clin Oncol 1995c; 13: 2417-2426.
83. Jones AL, Hill AS, Soukop M et al. Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. Lancet 1991; 338: 483-487.
84. Jordan NS, Schauer PK, Schauer A et al. The effect of administration rate on cisplatin-induced emesis. J Clin Oncol 1985; 3: 559-561.
85. Jovanovic-Micic D, Samardzic R, Beleslin DB. The role of α-adrenergic mechanisms within the area postrema in dopamine-induced emesis. Eur J Pharmacol 1995; 272: 21-30.
86. Kaasa S, Kvaløy S, Dicato M et al. A comparison of ondansetron with metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting: a randomized, double-blind study. Eur J Cancer 1990; 26(3): 311-314.
87. Kaye SB. How should nausea be assessed in patients receiving chemotherapy? Cancer Treat Rep 1991; 18:85-93.
88. Kerr DJ, Graham J, Blackie RG et al. The relationship between steady state metoclopramide levels and control of emesis treatment with cis-platinum. Br J Clin Pharmacol 1985; 20: 426-427.
89. 3 receptors in rat brain using radioligand binding. Nature 1987; 330: 746-748.
90. 3H]-GR 65630 in rat brain using quantitative autoradiography. Neurosci Lett 1988; 94: 156-160.
91. Kris MG, Tyson LB, Gralla RJ et al. Extrapyramidal reactions with high-dose metoclopramide. N Engl J Med 1983; 309: 433.
92. Kris MG, Gralla RJ, Tyson LB et al. Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone, and diphenhydramine. Cancer 1985; 55: 527-534.
93. Kris MG, Gralla RJ, Tyson LB, Clark RA, Cirrincione C, Groshen S. Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol 1989; 7: 108-114.
94. Lebeau B, Depierre A, Giovannini M et al. The efficacy of a combination of ondansetron, methylprednisolone and metopimazine in patients previously uncontrolled with a dual antiemetric treatment in cisplatin-based chemotherapy. Ann Oncol 1997; 8: 887-892.
95. Leibundgut U, Lancranjan I. First results with ICS 205-930 (5-HT receptor antagonist) in prevention of chemotherapy induced emesis. Lancet 1987; i: 1198.
96. Leslie RA. Comparative aspects of the area postrema: fine structural considerations help to determine its function. Cell Molec Neurobiol 1986; 6: 95120.
97. 3 recognition sites on vagal afferent terminals in the brainstem of the ferret. Neuroscience 1990; 38: 667-673.
98. Lindstrom PA, Brizzee K.R. Relief of intractable vomiting from surgical lesions in the area postrema. J Neurosurg 1962; 19: 228-236.
99. Livera P, Trojano M, Simone IL et al. Acute changes in blood CSF barrier permselectivity to serum proteins after intrathecal methotrexate and CNS irradiation. J Neurol 1985; 231: 336-339.
100. Love RR, Leventhal H, Easterling MA, Nerenz DR. Side effects and emotional distress during cancer chemotherapy. Cancer 1989; 63: 604-612.
101. Lucot JB, Crampton GH. 8-OH-DPAT suppresses vomiting in the cat elicited by motion, cisplatin orxylazine. Pharmacol Biochem Behav 1989; 33:627-631.
102. Markman M, Sheidler V, David MS et al. Antiemetic efficacy of dexamethasone. Randomized, double-blind, cross-over study with prochlorperazine in patients receiving cancer chemotherapy. N Engl J Med 1984; 311: 549-552.
103. Marschner NW, Adler M, Nagel GA, Christmann D, Fenzl E, Upadhyaya B. Double-blind randomised trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide. Eur J Cancer 1991; 27: 1137-1140. [Erratum, Eur J Cancer 1991; 27: 1717.
104. Martin M, Diaz-Rubio E, Sanchez A, Almenarez J, Lopéz-Vega JM. The natural course of emesis after carboplatin treatment. Acta Oncol 1990; 29: 593-595.
105. 3 antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cispiatin-induced emesis. N Engl J Med 1990; 322: 816-821.
106. McCarthy LE & Borison HL. Cisplatin-induced vomiting eliminated by ablation of the area postrema in cats. Cancer Treat Rep 1984; 68: 401-404.
107. McDermed JE, Cohen JL, Joseph C, Strum SB. Clinical pharmacokinetics of high-dose metoclopramide in cancer patients receiving cispiatin therapy. J Clin Oncol 1985; 3: 1400-1408.
108. Melander A. Influence of food on the bioavailability of drugs. Clin Pharma- cokin 1978; 3: 337-351.
109. Meyer BR, Lewin M, Drayer DE et al. Optimizing metociopramide control of cispiatin-induced emesis. Ann Intern Med 1984; 100: 393-395.
110. Miller AD, Nonaka S, Jakus J. Brain areas essential or non-essential for emesis. Brain Research 1994; 647: 225-264.
111. Miner WD, Sanger GJ. Inhibition of cispiatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism. Br J Pharmacol 1986; 88: 497-499.
112. Moertel CG & Reitemeier CG. Controlled clinical studies of orally administered antiemetic drugs. Gastroenterology 1969; 56(3): 262-268.
113. Moertel CG ̀ Reitemeier RJ. Controlled studies of metopimazine for the treatment of nausea and vomiting. J Clin Pharmacol 1973; 13: 283-287.
114. Morran C, Smith DC, Anderson DA, McArdle CS. Incidence of nausea and vomiting with cytotoxic chemotherapy: a prospective randomised trial of antiemetics. BMJ 1979; 19: 1323-1324.
115. Morrow GR. The assessment of nausea and vomiting: past problems, current issues, and suggestions for future research. Cancer 1984; 53(suppl 10): 2267-2278.
116. Morrow GR. The effect of a susceptibility to motion sickness on the side effects of cancer chemotherapy. Cancer 1985; 55: 2766-2770.
117. Morrow GR, Hickok JT, Rosenthal SN. Progress in reducing nausea and emesis. Comparisons of ondansetron (Zofran), granisetron (Kytril), and tropisetron (Navoban). Cancer 1995; 76: 343-357.
118. Navari RM. Comparison of intermittent versus continuous infusion metoclopramide in control of acute nausea induced by cisplatin chemotherapy. J Clin Oncol 1989; 7: 943-946.
119. Navari RM, Madajewicz S, Anderson N et al. Oral ondansetron for the control of cispiatin-induced delayed emesis: a large multicenter, double-blind, randomized comparative trial of ondansetron versus placebo. J Clin Oncol 1995; 13:2408-2416.
120. 1A receptor agonists in suncus murinus. Jpn J Pharmacol 1994; 64: 109-114.
121. 2 receptor agonist in suncus murinus. Br J Pharmacol 1995; 114: 931-934.
122. Olver IN, Simon RM, Aisner J. Antiemetic studies: a methodological discussion. Cancer Treat Rep 1986; 70: 555-563.
123. Olver IN, Matthews JP, Bishop JF, Smith RA. The roles of patient and observer assessments in anti-emetic trials. Eur J Cancer 1994; 30A: 1223-1227.
124. Olver IN, Wolf M, Laidlaw C et al. A randomised double-blind study of high-dose intravenous prochlorperazine versus high-dose metoclopramide as antiemetics for cancer chemotherapy. Eur J Cancer 1992; 28A: 1798-1802.
125. Olver IN, Webster LK, Bishop JF, Clarke J, Hillcoat BL. A dose finding study of prochlorperazine as an antiemetic for cancer chemotherapy. Eur J Cancer Clin Oncol 1989; 25: 1457-1461.
126. Onsrud M, Moxnes A, Sollien A et al. High-dose versus low-dose metoclopramide in the prevention of cispiatin-induced emesis. Cancer 1988; 61: 2429-2432.
127. 1-receptors in the rat brain: an autoradiographic study. Neuroscience 1981; 6: 15-37.
128. Pater JL, Willan AR. Methodologic issues in trials of antiemetics. J Clin Oncol 1984; 2: 484-487.
129. Perez EA. Review of the preclinical pharmacology and comparative efficacy of 5-hydroxytryptamine-3 receptor antagonists for chemotherapy-induced emesis. J Clin Oncol 1995; 13: 1036-1043.
130. Peroutka SJ. Chemotherapeutic agents do not interact with neurotransmitter receptors. Cancer Chemother Pharmacol 1987; 19: 131-132.
131. Peroutka SJ, Snyder SH. Relationship of neuroleptic drug effects at brain dopamine, serotonin, α-adrenergic, and histamine receptors to clinical potency. Am J Psychiatry 1980; 137: 1518-1522.
132. Peroutka SJ, Snyder SH. Antiemetics: neurotransmitter receptor binding predicts therapeutic actions. Lancet 1982; i: 658-659.
133. 3 recognition sites in rat cortical membranes. Eur J Pharmacol 1988; 14: 297-299.
134. Pocock SJ. Crossover trials. In: Pocock SJ. Clinical trials: a practical approach. Chichester, England: John Wiley, 1983: 110-122.
135. 3 receptors in mammalian hindbrain. Trends Pharmacol Sci 1990; 11: 135-137.
136. 3H]BRL 43694, binds to presynaptic sites in the nucleus tractus solitarius of the rat. Neuropharmacol 1989; 28(12): 1367-1376.
137. 3 receptor binding sites in human dorsal vagal complex. Eur J Pharmac 1989; 174: 127-130.
138. Roila F, Tonato M, Basurto C et al. Antiemetic activity of high doses of metoclopramide combined with methylprednisolone versus metoclopramide alone in cisplatin-treated patients: A randomized, double-blind trial of the Italian Oncology Group for Clinical Research. J Clin Oncol 1987; 5: 141-149.
139. Roila F, Basurto C, Minotti V et.al. Methylprednisolone versus metoclopramide for prevention of nausea and vomiting in breast cancer patients treated with cyclophosphamide, methotrexate and 5-fluorouracil: a double-blind randomized study. Oncology 1988; 45: 346-349.
140. Roila F, Basurto C, Bracarda S et al. Double-blind crossover trial of single vs. divided doses of metoclopramide in a combined regimen for treatment of cisplatin-induced emesis. Eur J Cancer 1991a;27(2): 119-121.
141. Roila F, Tonato M, Basurto C et al. Protection from nausea and vomiting in cisplatin-treated patients: high-dose metoclopramide combined with methylprednisolone versus metoclopramide combined with dexamethasone and diphenhydramine. A study of the Italian Oncology Group for Antiemetic Research: J Clin Oncol 1989; 7: 1693-1700.
142. Roila F, Tonato M, Cognetti F et al. Prevention of cisplatin-induced emesis: a double-blind multicenter randomized cross-over study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol 1991b; 9: 675-678.
143. Saller R, Hellenbrecht D, Hellstern A, Hess H. Improved benefit/risk ratio of higher-dose metoclopramide therapy during cisplatin-induced emesis. Eur J Clin Pharmacol 1985; 29: 311-312.
144. Seynaeve C, Schuller J, Buser K et al. Comparison of the antiemetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis: a multicentre, double-blind, randomised, parallel group study. Br J Cancer 1992; 66: 192-197.
145. 2 antagonist metopimazine (MPZ) in 223 women with breast cancer receiving multiple cycles of moderately emetogenic chemotherapy (CT). Support Care Cancer 1995; 3(5): 335.
146. Smith WL, Callaham EM, Alphin RS. The emetic activity of centrally administered cisplatin in cats and its antagonism by zacopride. J Pharm Pharmacol 1988; 40: 142-143.
147. Smith DB, Newlands ES, Rustin GJS, Begent RHJ, Howells N, McQuade B, Bagshawe KD. Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy. Lancet 1991; 338: 487-490.
148. Smyth JF, Coleman RE, Nicolson M et al. Does dexamethasone enhance control of acute cisplatin induced emesis by ondansetron? BMJ 1991; 303: 1423-1426.
149. 3, receptor an- tagonist, with a metoclopramide-containing antiemetic cocktail in the prevention of cisplatin-induced emesis. Cancer 1994a; 73: 445-454.
150. Sorbe B, Högberg T, Himmelmann A, Schmidt M, Räisänen I, Stockmeyer M, de Bruijn KM. Efficacy and tolerability of tropisetron in comparison with a combination of tropisetron and dexamethasone in the control of nausea and vomiting induced by cisplatin-containing chemotherapy. Eur J Cancer 1994b; 30A(5): 629-634.
151. Soukop M, McQuade B, Hunter E et al. Ondansetron compared with metoclopramide in the control of emesis and quality of life during repeated chemotherapy for breast cancer. Oncology 1992; 49: 295-304.
152. Stephen LC, Rine J et al. The role of prostaglandins in the excessive nausea and vomiting after intravascular cis-platinum therapy. Gynecol Oncol 1981; 12: 89-91.
153. Stephens SH, Silvey L, Wheeler RH. A randomized, double-blind comparison of the antiemetic effect of metoclopramide and lorazepam with or without dexamethasone in patients receiving high-dose cisplatin. Cancer 1990; 66: 443-446.
154. Strum SB, McDermed JE, Liponi DF. High-dose intravenous metoclopramide versus combination high-dose metoclopramide and intravenous dexamethasone in preventing cisplatin-induced nausea and emesis: a single-blind cross-over comparison of antiemetic efficacy. J Clin Oncol 1985; 3: 245-251.
155. R i et åbent og et dobbel-blindt forsøg. Ugeskr Laeger 1976; 138: 1769-1770.
156. Sullivan JR, Leyden MJ, Bell R. Decreased cisplatin-induced nausea and vomiting with chronic high alcohol ingestion. N Engl J Med 1983; 309: 796.
157. Thumas LJ. Ueber das Brechcentrum und über die Wirkung einiger pharmakologischer Mittel auf dasselbe. Archieves für Patologische Anatomie 1891; 123: 44-69.
158. Tonato M, Roila F, Del Favero A. Methodology of antiemetic trials: a review. Ann Oncol 1991; 2: 107-114.
159. Vallejo C, Rabinovich M, Leone B, Gonzales J. Toxicity and dose response of intravenous (I.V.) metopimazine (MTZ) as preventive of high-dose cisplatin (CDDP)-induced emesis. Proc Am Soc Clin Oncol 1988; 7: 286.
160. Van Wijngaarden I, Tulp MThM, Soudijn W. The concept of selectivity in 5HT receptor research. Eur J Pharmacol 1990; 188: 301-312.
161. Waeber C, Dixon K, Hoyer D, Palacios JM. Localisation by autoradiography of neuronal 5-HT3 receptors in the mouse CNS. Eur J Pharmacol 1988; 151: 351-352.
162. Wamsley JK, Lewis MS, Young S et al. Autoradiographic localization of muscariniccholinergic receptors in rat brain stem. J Neuroscience 1981; 2: 176-191.
163. Wang SC & Borison HL. A new concept of organization of the central emetic mechanism: recent studies on sites of action of apomorphine, copper sulphate and cardiac glycosides. Gastroenterology 1952; 22: 1-12.
164. Warr D, Wilson A, Fine S et al. Superiority of granisetron to dexamethasone plus prochlorperazine in the prevention of chemotherapy-induced emesis. J Natl Cancer Inst 1991; 83: 1169-1173.
165. Warr D, Wilan A, Venner P et al. A randomised, double-blind comparison of granisetron with high-dose metoclopramide, dexamethasone and diphenhydramine for cisplatin-induced emesis. Eur J Cancer 1993; 29A(1): 33-36.
166. Warrington PS, Allan SG, Cornbleet MA et al. Optimising antiemesis in cancer chemotherapy: efficacy of continuous versus intermittent infusion of high dose metoclopramide in emesis induced by cisplatin. BMJ 1986; 293: 1334-1337.
167. 1 receptor. Br J Pharmacol 1995; 115: 84-94.
168. Wilcox PM, Fetting JH, Nettesheim K.M, Abeloff MD. Anticipatory vomiting in women receiving cyclophosphamide, methotrexate and 5-fluorouracil (CMF) adjuvant chemotherapy for breast cancer. Cancer Treat Rep 1982; 66: 1601-1604.